Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer

BACKGROUND: Despite major advancements in immunotherapy among a number of solid tumors, response rates among ovarian cancer patients remain modest. Standard treatment for ovarian cancer is still surgery followed by taxane- and platinum-based chemotherapy. Thus, there is an urgent need to develop nov...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartl, Christina A., Bertschi, Adrian, Puerto, Regina Bou, Andresen, Carolin, Cheney, Emily M., Mittendorf, Elizabeth A., Guerriero, Jennifer L., Goldberg, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668091/
https://www.ncbi.nlm.nih.gov/pubmed/31362778
http://dx.doi.org/10.1186/s40425-019-0654-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668091/
https://www.ncbi.nlm.nih.gov/pubmed/31362778
http://dx.doi.org/10.1186/s40425-019-0654-5

Ejemplares similares